Woodward Diversified Capital LLC Purchases 192,808 Shares of Genelux Corporation (NASDAQ:GNLX)

Woodward Diversified Capital LLC grew its stake in shares of Genelux Corporation (NASDAQ:GNLX - Free Report) by 15.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,461,113 shares of the company's stock after buying an additional 192,808 shares during the period. Genelux accounts for approximately 2.8% of Woodward Diversified Capital LLC's holdings, making the stock its 7th biggest holding. Woodward Diversified Capital LLC owned approximately 4.22% of Genelux worth $3,945,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Virtu Financial LLC purchased a new stake in Genelux during the 4th quarter worth $25,000. Advisor Resource Council purchased a new stake in Genelux during the 1st quarter worth $34,000. Raymond James Financial Inc. purchased a new stake in Genelux during the 4th quarter worth $41,000. 5T Wealth LLC purchased a new stake in Genelux during the 1st quarter worth $49,000. Finally, Miracle Mile Advisors LLC boosted its position in Genelux by 60.0% during the 1st quarter. Miracle Mile Advisors LLC now owns 40,000 shares of the company's stock worth $108,000 after purchasing an additional 15,000 shares during the period. 37.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price target on shares of Genelux in a research report on Monday, March 31st. Benchmark cut their price objective on shares of Genelux from $25.00 to $23.00 and set a "speculative buy" rating on the stock in a report on Thursday, May 8th. Finally, Wall Street Zen upgraded shares of Genelux from a "sell" rating to a "hold" rating in a report on Saturday, July 12th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $17.75.

Genelux Stock Performance

Shares of Genelux stock traded down $0.07 during trading on Friday, reaching $3.33. The company had a trading volume of 45,235 shares, compared to its average volume of 172,905. The company has a market cap of $125.74 million, a price-to-earnings ratio of -3.78 and a beta of -0.34. The firm's fifty day moving average is $2.82 and its 200-day moving average is $3.16. Genelux Corporation has a fifty-two week low of $1.60 and a fifty-two week high of $5.89.

Genelux (NASDAQ:GNLX - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.03. On average, research analysts anticipate that Genelux Corporation will post -0.88 EPS for the current fiscal year.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.